{"version":"1.0","type":"link","title":"Glecirasib plus sitneprotafib in patients with KRAS-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.","author_name":"Zhong J 외","author_url":"https://prs-insight.online/author/Zhong%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97888","thumbnail_width":1200,"thumbnail_height":630}